Drugs / imalumab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01765790 | Jun 2012 → Jul 2016 | colorectal adenocarcinoma | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02540356 | Nov 2015 → May 2016 | cancer | Baxalta now part of Shire | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02448810 | Jun 2015 → Feb 2017 | colorectal cancer | Baxalta now part of Shire | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | imalumab | “Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory Factor antibody in advanced solid tumours.” PMID 32207164 ↗ Apr 2020 |
| Known as | BAX-069 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650294 ↗ |
| Known as | BAX69 | “Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory Factor antibody in advanced solid tumours.” PMID 32207164 ↗ Apr 2020 |
| Action | Inhibit | “imalumab, an oxMIF inhibitor” PMID 32207164 ↗ Apr 2020 |
| Modality | Protein / enzyme biologic | “a fully human recombinant antioxidized macrophage migration inhibitory factor antibody” PMID 32207164 ↗ Apr 2020 |
| Route | Intravenous | “patients with solid tumours received doses from 1 to 50 mg/kg IV every 2 weeks” PMID 32207164 ↗ Apr 2020 |
| Target | MIF | “imalumab, an oxMIF inhibitor” PMID 32207164 ↗ Apr 2020 |